Clinical Trial Search

Primary: Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at Baseline — 19.6; 14; 12.6 SFCs/10⁶ PBMCs

Primary: The Achievement Rate of HbA1c (<7%) — 63; 65; 58; 64 Participants — p=0.9917

Primary: Placebo-controlled Period: Change From Baseline in the Number of MMDs at Weeks 1 - 4 — -6.85; -3.66 days/month — p=<0.0001

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Typical Number of Drinks Per Occasion — 3.75; 3.67 Typical number of drinks per occasion

Primary: Dietary Self-monitoring Frequency, Overall — 23.0; 24.3; 22.0; 25.3 days — p=>0.05

Primary: Number of Participants Reaching Proficiency Level 2: Unsupervised BCI Performance — 1 Participants

Primary: Dose Limiting Toxicities in Part 1 and Part 1A — 0; 0; 1; 1 Participants

Primary: Proportion of Participants Who Achieved and Maintained Reduction in Serum Uric Acid (sUA) < 6 Milligrams Per Deciliter (mg/dL) for At Least 80% of The Time During…

Primary: Number of Dose Limiting Toxicities (DLTs) — 1; 1; 0; 0 Dose limiting toxicities

Primary: Cardiac Output Reserve (Qc) — 3.3; 3.8 Liters/Min

Primary: Feasibility of the Prehabilitation Program — 19 Participants

Primary: Impedance Measurements — 0.36 kOhm

Primary: Maximum Observed Concentration (Cmax) of BMS-986165 and BMT-153261 in Breast Milk — 211.0; 74.09 ng/mL

Primary: Framework Analysis Using the Theoretical Framework of Acceptability as a Guiding Framework — 4; 4; 4; 4 Participants